Clinical trials / NCT05714345
NCT05714345Phase 2Terminated

Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy

Study sponsor: Allogene Therapeutics

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov recordCSV export · Pro
Primary completion2024-02-20Actual
Enrollment · participants2Actual
Source updated2026-03-02Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features

· 4 fields changed

Primary outcomes · main study measures

Text edit · unverified significance
− Previous value

measure: To assess the clinical efficacy of ALLO-647 (in a lymphodepletion regimen before ALLO-501A) compared to FC alone as measured by PFS and assessed by IRC in subjects with R/R (Relapsed / Refractory) LBCL (Large B Cell Lymphoma)

+ Updated value

measure: Progression-Free Survival (PFS) of a Lymphodepletion Regimen Containing FCA vs FC Alone Per Independent Review Committee

The saved outcome text may be shortened. Check the source for full wording.

Participant count type

Recorded edit
− Previous value

Estimated

+ Updated value

Actual

Enrollment · participant count

Recorded edit
− Previous value

count: 70; type: ESTIMATED

+ Updated value

count: 2; type: ACTUAL

Recruitment status

Recorded edit
− Previous value

Active not recruiting

+ Updated value

Terminated

Check registry source